U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i

2′, 3′-Dideoxyinosine Inhibits the Humoral Immune Response in Female B6C3F1 Mice by Targeting the B Lymphocyte

Public Domain


Details

  • Personal Author:
  • Description:
    2',3'-Dideoxyinosine (ddI) is a purine nucleoside analog currently being used for the treatment of HIV-positive individuals and patients with AIDS. Preliminary immunotoxicity studies have shown that a consequence of ddI treatment in female B6C3F1 mice is the inhibition of the humoral immune response. This effect was dose dependent in a range of 100 to 1000 mg/kg with a no observed adverse effect level of less than 100 mg/kg for a 28-day treatment period. These studies were undertaken to investigate the immune cell target of ddI and to determine the mechanism of this toxicity. B6C3F1 mice were treated with 1000 mg/kg/day by oral gavage for 28 days. The B lymphocyte was identified as the cellular target of ddI through separation-reconstitution experiments of the adherent and nonadherent cell populations and of the T and B lymphocyte populations. These studies revealed a deficit in the ability of the nonadherent cells from ddI-treated mice to mount a normal antibody response to sRBC. A further separation of the nonadherent cells into T and B cells revealed a decreased ability of ddI-treated B cells to develop specific humoral immunity. Additional studies were undertaken to determine the mechanism by which ddI is affecting the B cell. Surface marker analysis of splenocytes revealed no difference in the cell populations between vehicle- and ddI-treated mice. B cell proliferation was also unaffected as shown by incubation with either a polyclonal stimulator, lipopolysaccharide, or anti-IgM plus IL-4. These results indicate that the primary cellular target of ddI is the B lymphocyte. [Description provided by NIOSH]
  • Subjects:
  • Keywords:
  • ISSN:
    0041-008X
  • Document Type:
    Text
  • Genre:
    Journal Article
  • Place as Subject:
  • CIO:
    National Institute for Occupational Safety and Health (NIOSH)
  • Division:
    HELD - Health Effects Laboratory Division
  • Topic:
    Workplace Safety & Health
  • Location:
    North America
  • Pages in Document:
    260-267
  • Volume:
    145
  • Issue:
    2
  • NIOSHTIC Number:
    nn:20033926
  • Citation:
    Toxicol Appl Pharmacol 1997 Aug; 145(2):260-267
  • Contact Point Address:
    Albert E. Munson, National Institute for Occupational Safety and Health (NIOSH), 1095 Willowdale Road, Morgantown, WV 26505
  • Federal Fiscal Year:
    1997
  • Peer Reviewed:
    True
  • Source Full Name:
    Toxicology and Applied Pharmacology
  • Collection(s):
  • Main Document Checksum:
    urn:sha-512:32ff6764a888e1c019d030b1544855748289c2e77e28824424fbbabddb0d536f9d65d47312f37f8b8002de0ea1267399e455c70e60b93441fb38ff12bc04b3cd
  • Download URL:
  • File Type:
    Filetype[PDF - 195.61 KB ]
PREVIOUS
ON THIS PAGE
Details
CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
BACK TO TOP